CGAS/STING pathway in cancer: Jekyll and hyde story of cancer immune response

International Journal of Molecular Sciences

Volumn 18, Issue 11, 2017, Pages

  Bose, Debojit ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cancer; Cancer immunotherapy; CGAS; Cyclic guanosine monophosphate adenosine monophosphate (cGAMP); Immunity; STING

Indexed keywords

CASPASE 3; CISPLATIN; DIMETHYLBENZ[A]ANTHRACENE; ETOPOSIDE; FLUOROURACIL; GENOMIC DNA; INTERFERON; INTERFERON RECEPTOR; MITOCHONDRIAL DNA; TOLL LIKE RECEPTOR; VADIMEZAN; ANTINEOPLASTIC AGENT; CYCLIC GMP AMP SYNTHASE; CYCLIC NUCLEOTIDE; DINUCLEOTIDE; PROTEIN; STIMULATOR OF INTERFERON GENES PROTEIN; SYNTHETASE; UNCLASSIFIED DRUG; MB21D1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NUCLEOTIDYLTRANSFERASE;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA DAMAGE; ENTERITIS; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASM; METASTATIC MELANOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; DRUG TARGETING; INTERFERON PRODUCTION; MAMMAL; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEOTIDYLTRANSFERASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 85035039244     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18112459     Document Type: Review

References (59)

1. Hellstrom, K.E.; Hellstrom, I. Cellular immunity against tumor antigens. Adv. Cancer Res. 1969, 12, 167-223.
2. Prehn, R.T. Tumor specific immunity to nonviral tumors. Proc. Can. Cancer Conf. 1963, 5, 387-395.
3. Chen, Q.; Sun, L.; Chen, Z.J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 2016, 17, 1142-1149.
4. Burdette, D.L.; Monroe, K.M.; Sotelo-Troha, K.; Iwig, J.S.; Eckert, B.; Hyodo, M.; Hayakawa, Y.; Vance, R.E. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478, 515-518.
5. Yin, Q.; Tian, Y.; Kabaleeswaran, V.; Jiang, X.; Tu, D.; Eck, M.J.; Chen, Z.J.; Wu, H. Cyclic di-GMP sensing via the innate immune signaling protein STING. Mol. Cell 2012, 46, 735-745.
6. Barker, J.R.; Koestler, B.J.; Carpenter, V.K.; Burdette, D.L.; Waters, C.M.; Vance, R.E.; Valdivia, R.H. STING-dependent recognition of cyclic di-AMP mediates Type I interferon responses during chlamydia trachomatis infection. mBio 2013, 4, e00018-13.
7. Dey, B.; Dey, R.J.; Cheung, L.S.; Pokkali, S.; Guo, H.; Lee, J.H.; Bishai, W.R. A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nat. Med. 2015, 21, 401-406.
8. Gao, D.; Li, T.; Li, X.D.; Chen, X.; Li, Q.Z.; Wight-Carter, M.; Chen, Z.J. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc. Natl. Acad. Sci. USA 2015, 112, E5699-E5705.
9. Corrales, L.; Gajewski, T.F. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine 2016, 77, 245-247.
10. Wang, H.; Hu, S.; Chen, X.; Shi, H.; Chen, C.; Sun, L.; Chen, Z.J. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl. Acad. Sci. USA 2017, 114, 1637-1642.
11. Li, T.; Cheng, H.; Yuan, H.; Xu, Q.; Shu, C.; Zhang, Y.; Xu, P.; Tan, J.; Rui, Y.; Li, P. et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci. Rep. 2016, 6, 19049.
12. Deng, L.; Liang, H.; Xu, M.; Yang, X.; Burnette, B.; Arina, A.; Li, X.D.; Mauceri, H.; Beckett, M.; Darga, T. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced Type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41, 843-852.
13. Woo, S.R.; Fuertes, M.B.; Corrales, L.; Spranger, S.; Furdyna, M.J.; Leung, M.Y.; Duggan, R.; Wang, Y.; Barber, G.N.; Fitzgerald, K.A. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41, 830-842.
14. Ahn, J.; Barber, G.N. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr. Opin. Immunol. 2014, 31, 121-126.
15. Ahn, J.; Gutman, D.; Saijo, S.; Barber, G.N. STING manifests self DNA-dependent inflammatory disease. Proc. Natl. Acad. Sci. USA 2012, 109, 19386-19391.
16. Ahn, J.; Ruiz, P.; Barber, G.N. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J. Immunol.2014, 193, 4634-4642.
17. Gall, A.; Treuting, P.; Elkon, K.B.; Loo, Y.M.; Gale, M., Jr.; Barber, G.N.; Stetson, D.B. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36, 120-131.
18. Liu, Y.; Jesus, A.A.; Marrero, B.; Yang, D.; Ramsey, S.E.; Sanchez, G.A.M.; Tenbrock, K.; Wittkowski, H.; Jones, O.Y.; Kuehn, H.S. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371, 507-518.
19. Woo, S.R.; Corrales, L.; Gajewski, T.F. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015, 36, 250-256.
20. Harlin, H.; Meng, Y.; Peterson, A.C.; Zha, Y.; Tretiakova, M.; Slingluff, C.; McKee, M.; Gajewski, T.F. Chemokine expression in melanoma metastases associated with cd8+ T-cell recruitment. Cancer Res. 2009, 69, 3077-3085.
21. Dunn, G.P.; Bruce, A.T.; Sheehan, K.C.; Shankaran, V.; Uppaluri, R.; Bui, J.D.; Diamond, M.S.; Koebel, C.M.; Arthur, C.; White, J.M. et al. A critical function for Type I interferons in cancer immunoediting. Nat. Immunol.2005, 6, 722-729.
22. Qin, Z.; Kim, H.J.; Hemme, J.; Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J. Exp. Med. 2002, 195, 1479-1490.
23. Le Bon, A.; Schiavoni, G.; D’Agostino, G.; Gresser, I.; Belardelli, F.; Tough, D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14, 461-470.
24. Montoya, M.; Schiavoni, G.; Mattei, F.; Gresser, I.; Belardelli, F.; Borrow, P.; Tough, D.F. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002, 99, 3263-3271.
25. Diamond, M.S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G.P.; Archambault, J.M.; Lee, H.; Arthur, C.D.; White, J.M.; Kalinke, U. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208, 1989-2003.
26. Burnette, B.C.; Liang, H.; Lee, Y.; Chlewicki, L.; Khodarev, N.N.; Weichselbaum, R.R.; Fu, Y.X.; Auh, S.L. The efficacy of radiotherapy relies upon induction of Type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71, 2488-2496.
27. Spaapen, R.M.; Leung, M.Y.; Fuertes, M.B.; Kline, J.P.; Zhang, L.; Zheng, Y.; Fu, Y.X.; Luo, X.; Cohen, K.S.; Gajewski, T.F. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J. Immunol. 2014, 193, 4254-4260.
28. Zhu, Q.; Man, S.M.; Gurung, P.; Liu, Z.; Vogel, P.; Lamkanfi, M.; Kanneganti, T.D. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J. Immunol.2014, 193, 4779-4782.
29. Ho, S.S.; Zhang, W.Y.; Tan, N.Y.; Khatoo, M.; Suter, M.A.; Tripathi, S.; Cheung, F.S.; Lim, W.K.; Tan, P.H.; Ngeow, J. et al. The DNA structure-specific endonuclease mus81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity 2016, 44, 1177-1189.
30. Ahn, J.; Xia, T.; Konno, H.; Konno, K.; Ruiz, P.; Barber, G.N. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 2014, 5, 5166.
31. Vanpouille-Box, C.; Alard, A.; Aryankalayil, M.J.; Sarfraz, Y.; Diamond, J.M.; Schneider, R.J.; Inghirami, G.; Coleman, C.N.; Formenti, S.C.; Demaria, S. DNA exonuclease TREX1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 2017, 8, 15618.
32. Carroll, E.C.; Jin, L.; Mori, A.; Munoz-Wolf, N.; Oleszycka, E.; Moran, H.B.T.; Mansouri, S.; McEntee, C.P.; Lambe, E.; Agger, E.M. et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of Type I interferons. Immunity 2016, 44, 597-608.
33. Mackenzie, K.J.; Carroll, P.; Martin, C.A.; Murina, O.; Fluteau, A.; Simpson, D.J.; Olova, N.; Sutcliffe, H.; Rainger, J.K.; Leitch, A. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 2017,548, 461-465.
34. Ohkuri, T.; Ghosh, A.; Kosaka, A.; Sarkar, S.N.; Okada, H. Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology 2015, 4, e999523.
35. Ohkuri, T.; Ghosh, A.; Kosaka, A.; Zhu, J.; Ikeura, M.; David, M.; Watkins, S.C.; Sarkar, S.N.; Okada, H. STING contributes to antiglioma immunity via triggering Type I IFN signals in the tumor microenvironment. Cancer Immunol. Res. 2014, 2, 1199-1208.
36. Xia, T.; Konno, H.; Ahn, J.; Barber, G.N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016, 14, 282-297.
37. Klarquist, J.; Hennies, C.M.; Lehn, M.A.; Reboulet, R.A.; Feau, S.; Janssen, E.M. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 2014, 193, 6124-6134.
38. Cerboni, S.; Jeremiah, N.; Gentili, M.; Gehrmann, U.; Conrad, C.; Stolzenberg, M.C.; Picard, C.; Neven, B.; Fischer, A.; Amigorena, S. et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 2017, 214, 1769-1785.
39. Larkin, B.; Ilyukha, V.; Sorokin, M.; Buzdin, A.; Vannier, E.; Poltorak, A. Cutting edge: Activation of STING in T cells induces Type I IFN responses and cell death. J. Immunol. 2017, 199, 397-402.
40. Xia, T.; Konno, H.; Barber, G.N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 2016, 76, 6747-6759.
41. Gajewski, T.F.; Schreiber, H.; Fu, Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14, 1014-1022.
42. Corrales, L.; Glickman, L.H.; McWhirter, S.M.; Kanne, D.B.; Sivick, K.E.; Katibah, G.E.; Woo, S.R.; Lemmens, E.; Banda, T.; Leong, J.J. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015, 11, 1018-1030.
43. Pang, J.H.; Cao, Z.; Joseph, W.R.; Baguley, B.C.; Ching, L.M. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur. J. Cancer 1998, 34, 1282-1289.
44. Conlon, J.; Burdette, D.L.; Sharma, S.; Bhat, N.; Thompson, M.; Jiang, Z.; Rathinam, V.A.; Monks, B.; Jin, T.; Xiao, T.S. et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 2013, 190, 5216-5225.
45. Wang, Z.; Celis, E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol. Immunother. 2015, 64, 1057-1066.
46. Chandra, D.; Quispe-Tintaya, W.; Jahangir, A.; Asafu-Adjei, D.; Ramos, I.; Sintim, H.O.; Zhou, J.; Hayakawa, Y.; Karaolis, D.K.; Gravekamp, C. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2014, 2, 901-910.
47. Nakamura, T.; Miyabe, H.; Hyodo, M.; Sato, Y.; Hayakawa, Y.; Harashima, H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J. Control Release 2015, 216, 149-157.
48. Tang, C.H.; Zundell, J.A.; Ranatunga, S.; Lin, C.; Nefedova, Y.; Del Valle, J.R.; Hu, C.C. Agonist-mediated activation of STING induces apoptosis in malignant B cells. Cancer Res. 2016, 76, 2137-2152.
49. Diner, E.J.; Burdette, D.L.; Wilson, S.C.; Monroe, K.M.; Kellenberger, C.A.; Hyodo, M.; Hayakawa, Y.; Hammond, M.C.; Vance, R.E. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013, 3, 1355-1361.
50. Demaria, O.; De Gassart, A.; Coso, S.; Gestermann, N.; Di Domizio, J.; Flatz, L.; Gaide, O.; Michielin, O.; Hwu, P.; Petrova, T.V. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl. Acad. Sci. USA 2015, 112, 15408-15413.
51. Temizoz, B.; Kuroda, E.; Ohata, K.; Jounai, N.; Ozasa, K.; Kobiyama, K.; Aoshi, T.; Ishii, K.J. TLR9 and STING agonists synergistically induce innate and adaptive type-I IFN. Eur. J. Immunol. 2015, 45, 1159-1169.
52. Baird, J.R.; Friedman, D.; Cottam, B.; Dubensky, T.W., Jr.; Kanne, D.B.; Bambina, S.; Bahjat, K.; Crittenden, M.R.; Gough, M.J. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2016, 76, 50-61.
53. Fu, J.; Kanne, D.B.; Leong, M.; Glickman, L.H.; McWhirter, S.M.; Lemmens, E.; Mechette, K.; Leong, J.J.; Lauer, P.; Liu, W. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to pd-1 blockade. Sci. Transl. Med. 2015, 7, 283ra252.
54. Hall, J.; Brault, A.; Vincent, F.; Weng, S.; Wang, H.; Dumlao, D.; Aulabaugh, A.; Aivazian, D.; Castro, D.; Chen, M. et al. Discovery of pf-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay. PLoS ONE 2017, 12, e0184843.
55. Huang, L.; Li, L.; Lemos, H.; Chandler, P.R.; Pacholczyk, G.; Baban, B.; Barber, G.N.; Hayakawa, Y.; McGaha, T.L.; Ravishankar, B. et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 2013, 191, 3509-3513.
56. Lemos, H.; Mohamed, E.; Huang, L.; Ou, R.; Pacholczyk, G.; Arbab, A.S.; Munn, D.; Mellor, A.L. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 2016, 76, 2076-2081.
57. Liang, D.; Xiao-Feng, H.; Guan-Jun, D.; Er-Ling, H.; Sheng, C.; Ting-Ting, W.; Qin-Gang, H.; Yan-Hong, N.; Ya-Yi, H. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-JUN/CCL22 signal. Biochim. Biophys. Acta 2015, 1852, 2494-2503.
58. Ahn, J.; Konno, H.; Barber, G.N. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene 2015, 34, 5302-5308.
59. Bose, D.; Su, Y.; Marcus, A.; Raulet, D.H.; Hammond, M.C. An RNA-based fluorescent biosensor for high-throughput analysis of the cGAS-cGAMP-STING pathway. Cell Chem. Biol. 2016, 23, 1539-1549.